Alpha Cognition (NASDAQ:ACOG) Posts Earnings Results, Misses Expectations By $0.01 EPS

Alpha Cognition (NASDAQ:ACOG) posted its quarterly earnings data on Thursday. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.01), Zacks reports. The company had revenue of $6.00 million during the quarter, compared to the consensus estimate of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 55.04%.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL net product revenue rose 71% sequentially to approximately $6 million in Q2 2026, with demand increasing each month and June marking the strongest month to date.
• Commercial adoption continued to deepen, with 1,347 active prescribers, 1,095 nursing homes placing prescriptions, and repeat utilization from approximately 76% of writers and 81% of prescribing homes.
• Management highlighted positive BEACON findings across cognition, neuropsychiatric symptoms, activities of daily living, and polypharmacy, while CONVERGE data is expected in Q3 2026 and RESOLVE remains on track to complete in Q2 2027.
• Payer and formulary expansion remains the largest near-term constraint; broad activation has been slower than expected, with coverage holding at roughly 74% and no significant formulary wins reported in Q2.
• The company reduced 2026 operating-expense guidance to $50 million-$54 million from $54 million-$58 million, ended Q2 with $41.4 million in cash, and reiterated its target of reaching operating profitability in 2027.

Alpha Cognition Stock Up 2.4%

Shares of NASDAQ:ACOG traded up $0.21 during midday trading on Friday, reaching $8.84. The company had a trading volume of 247,591 shares, compared to its average volume of 105,408. Alpha Cognition has a 1-year low of $4.50 and a 1-year high of $10.00. The stock has a market cap of $192.45 million, a PE ratio of -8.04 and a beta of 2.31. The business’s 50 day moving average price is $7.74 and its 200 day moving average price is $6.52.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ACOG shares. Raymond James Financial began coverage on Alpha Cognition in a report on Friday, July 10th. They issued an “outperform” rating and a $20.00 price target on the stock. Wall Street Zen raised Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday. Maxim Group assumed coverage on Alpha Cognition in a research note on Friday, May 29th. They issued a “buy” rating and a $12.00 target price on the stock. Craig Hallum reaffirmed a “buy” rating and set a $17.00 price target on shares of Alpha Cognition in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Alpha Cognition in a research note on Friday, May 22nd. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $16.75.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ACOG. Ikarian Capital LLC raised its stake in shares of Alpha Cognition by 11.6% during the 4th quarter. Ikarian Capital LLC now owns 1,056,259 shares of the company’s stock worth $6,866,000 after purchasing an additional 110,000 shares in the last quarter. Sphera Funds Management LTD. lifted its stake in Alpha Cognition by 67.6% in the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock valued at $3,690,000 after acquiring an additional 228,864 shares during the last quarter. Opaleye Management Inc. grew its position in shares of Alpha Cognition by 1,698.5% in the 4th quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock valued at $13,460,000 after acquiring an additional 1,955,642 shares during the period. Cantor Fitzgerald L. P. acquired a new position in shares of Alpha Cognition during the 4th quarter worth about $1,062,000. Finally, AWM Investment Company Inc. raised its holdings in shares of Alpha Cognition by 52.6% in the 4th quarter. AWM Investment Company Inc. now owns 1,672,168 shares of the company’s stock valued at $10,869,000 after purchasing an additional 576,516 shares during the period.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.